ReviewClinical medicine (London, England)2014
'Designer drugs': update on the management of novel psychoactive substance misuse in the acute care setting.
Review in Clinical medicine (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pharmacotherapy of Patients Taking New Psychoactive Substances: A Systematic Review and Analysis of Case Reports.Frontiers in psychiatry · 2021Pooled it
- Review
- Acute Kidney Injury (AKI) in Young Synthetic Cannabinoids Abusers.Biomedicines · 2022Review
- An Update on the Implications of New Psychoactive Substances in Public Health.International journal of environmental research and public health · 2022Review
- Comparison of LC-MS and LC-DAD Methods of Detecting Abused Piperazine Designer Drugs.Journal of clinical medicine · 2022Article
- Contribution of Illicit Drug Use to Pharmaceutical Load in the Environment: A Focus on Sub-Saharan Africa.Journal of environmental and public health · 2022Review
- Rapid Targeted Method of Detecting Abused Piperazine Designer Drugs.Journal of clinical medicine · 2021Article
- Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.World journal of clinical pediatrics · 2016Review
- Drug-induced hyperthermia in critical care.Journal of the Intensive Care Society · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of novel psychoactive substances ('legal highs' or 'designer drugs') is increasing worldwide. Patients misusing such substances have been reported to experience severe or prolonged side effects requiring admission to acute or critical care wards. These complications can be life threatening if misdiagnosed or mismanaged. As physicians have traditionally had less involvement with the management of such patients compared with their colleagues in emergency departments an update in the management of such patients is indicated. Here we present a summary of the management of those novel substances with the potential for serious complications based on a review of current literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.